Table 2.

Positive and negative syndrome scale total scores during the study (full analysis set, last observation carried forward)

	Placebo (n = 174)	Asenapine 5 mg bid (n = 173)	Asenapine 10 mg bid (n = 178)	Asenapine 5 mg bid − placebo	Asenapine 10 mg bid − placebo
At baseline
Mean	94.51	94.23	92.83
SD	17.26	18.06	17.42
End of treatment (day 42)
Mean	93.38	81.84	78.60
SD	25.30	26.10	25.01
Change from baseline to end of treatment
LSM	−0.95	−12.24	−14.17	−11.29	−13.22
SE	1.53	1.55	1.50	2.10	2.09
95 % CI	−3.95, 2.06	−15.28, −9.20	−17.12, −11.22	−15.42, −7.16	−17.33, −9.12
p valuea	–	–	–	<0.0001	<0.0001

^aFor between-group comparisons

bid twice daily, CI confidence interval, LSM least squares mean, SD standard deviation, SE standard error